
Opinion|Videos|February 24, 2025
Positioning Biosimilars in Clinical Practice
Panelists discuss how biosimilars are gaining traction through targeted education, cost-effectiveness analysis, and rigorous clinical validation, with providers increasingly integrating these alternatives by addressing knowledge barriers and demonstrating comparable therapeutic performance.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are providers positioning biosimilars in their treatment algorithms? What can be done to increase provider confidence in biosimilars?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
2
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
3
NIH F32 Grants Boost Early-Career Researchers’ Success
4
Intermountain Spans Time Zones, Cultures to Bring Oncology Care to Alaska
5

















































